These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 3358633

  • 1. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 2. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA, Greene K, Ahmad S, Vistica DT.
    Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359
    [Abstract] [Full Text] [Related]

  • 3. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
    Soble MJ, Dorr RT.
    Res Commun Chem Pathol Pharmacol; 1987 Feb 15; 55(2):161-80. PubMed ID: 3823607
    [Abstract] [Full Text] [Related]

  • 4. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 15; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 5. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 15; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 6. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Oct 15; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 8. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 15; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 15; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 11. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G, Zeller WJ.
    Anticancer Res; 1991 Jan 15; 11(6):2231-7. PubMed ID: 1776864
    [Abstract] [Full Text] [Related]

  • 12. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS.
    Cancer Res; 1988 May 15; 48(10):2764-7. PubMed ID: 3359437
    [Abstract] [Full Text] [Related]

  • 13. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 15; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 14. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 15; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
    Wu HY, Kang YJ.
    J Pharmacol Exp Ther; 1998 Nov 15; 287(2):515-20. PubMed ID: 9808675
    [Abstract] [Full Text] [Related]

  • 16. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 17. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
    Miller AC, Henderson BW.
    J Natl Cancer Inst; 1986 Aug 01; 77(2):505-10. PubMed ID: 3461211
    [Abstract] [Full Text] [Related]

  • 18. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 01; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 19. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
    Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA.
    Cancer Res; 1994 Aug 01; 54(15):4077-83. PubMed ID: 8033140
    [Abstract] [Full Text] [Related]

  • 20. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
    Prezioso JA, FitzGerald GB, Wick MM.
    J Invest Dermatol; 1992 Sep 01; 99(3):289-93. PubMed ID: 1512464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.